Stock News

Halcón Resources (HK) Reaches $4.25 After 8.00% Down Move; Alexion Pharmaceuticals (ALXN) Shorts Up By 7.8%

Halcón Resources Corporation (NYSE:HK) Logo

The stock of Halcón Resources Corporation (NYSE:HK) is a huge mover today! The stock decreased 2.75% or $0.12 during the last trading session, reaching $4.25. About 1.40 million shares traded. Halcón Resources Corporation (NYSE:HK) has declined 27.67% since June 12, 2017 and is downtrending. It has underperformed by 40.24% the S&P500. Some Historical HK News: ; 17/05/2018 – Halcon Resources Closes Above 50-Day Moving Average: Technicals; 28/03/2018 Halcon Resources Non-Deal Roadshow Set By Seaport for Apr. 4-5; 04/04/2018 – Halcón Resources Announces the Closing of the West Quito Draw Acquisition, the Expiration of its Monument Draw East Option and; 04/04/2018 – HALCON RESOURCES CORP – ELECTED NOT TO EXERCISE ITS PREVIOUSLY DISCLOSED MONUMENT DRAW EAST OPTION; 30/05/2018 – FLOWERING TREE CEO SACHDEVA SPEAKS AT SOHN CONFERENCE IN HK; 15/05/2018 – 2330.TW, $ASML.NL, 981.HK: China’s top state-backed contract chipmaker ordered highly advanced equipment with a price tag of $120 million; 15/05/2018 – Halcon Resources at Stephens Energy Executive Summit Tomorrow; 04/05/2018 – Victory Capital Buys New 1.5% Position in Halcon Re; 02/05/2018 – Halcon Resources 1Q Rev $49.3M; 03/04/2018 – HALCON RESOURCES HOLDER FRANKLIN RESOURCES REPORTS 6.8% STAKEThe move comes after 7 months negative chart setup for the $678.84M company. It was reported on Jun, 12 by Barchart.com. We have $3.91 PT which if reached, will make NYSE:HK worth $54.31M less.

Alexion Pharmaceuticals Inc (NASDAQ:ALXN) had an increase of 7.8% in short interest. ALXN’s SI was 4.50M shares in June as released by FINRA. Its up 7.8% from 4.17 million shares previously. With 2.57 million avg volume, 2 days are for Alexion Pharmaceuticals Inc (NASDAQ:ALXN)’s short sellers to cover ALXN’s short positions. The SI to Alexion Pharmaceuticals Inc’s float is 2.02%. The stock increased 0.98% or $1.14 during the last trading session, reaching $117.84. About 837,239 shares traded. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has risen 19.53% since June 12, 2017 and is uptrending. It has outperformed by 6.96% the S&P500. Some Historical ALXN News: ; 26/04/2018 – ALEXION PHARMACEUTICALS INC SEES 2018 NON-GAAP SHR $6.75 TO $6.90; 15/03/2018 – ALEXION PHARMACEUTICALS INC – ALXN1210 WAS GENERALLY WELL TOLERATED WITH A SAFETY PROFILE THAT IS CONSISTENT WITH THAT SEEN FOR SOLIRIS; 11/04/2018 – Alexion buying Swedish biotech for $855 million to broaden rare disease pipeline; 11/04/2018 – Alexion Makes $788 Million Bid for Sweden’s Wilson Therapeutics; 20/04/2018 – Alexion Provides Statement on Superior Court of Justice (STJ) Decision in Brazil Involving Soliris(R) (Eculizumab); 11/04/2018 – ALEXION PHARMACEUTICALS INC ALXN.O SAYS ALEXION WILL ACQUIRE WILSON THERAPEUTICS THROUGH A TENDER OFFER; 26/04/2018 – Alexion Pharmaceuticals Sees FY EPS $4.35-EPS $4.75; 25/05/2018 – Alexion: Wilson Therapeutics Holders Accept Offer; 11/04/2018 – Alexion To Acquire Wilson Therapeutics; 11/04/2018 – Alexion: Wilson Therapeutics Board Unanimously Recommends Shareholders Accept the Offer

Halcón Resources Corporation, an independent energy company, engages in the acquisition, production, exploration, and development of onshore oil and natural gas properties in the United States. The company has market cap of $678.84 million. The firm primarily holds interests in approximately 116,000 net acres, as well as 300 producing wells in the Bakken/Three Forks formations in North Dakota; and 20,901 net acres in the Southern Delaware Basin in Pecos and Reeves Counties, Texas, as well as has an option to acquire approximately 15,040 net acres in Ward and Winkler Counties, Texas. It has a 2.14 P/E ratio. As of December 31, 2016, it had estimated proved reserves of approximately 148.6 million barrels of oil equivalent comprising 119.6 million barrels of crude oil, 15.6 million barrels of natural gas liquids, and 80.2 billion cubic feet of natural gas.

Analysts await Halcón Resources Corporation (NYSE:HK) to report earnings on August, 1. After $-0.06 actual EPS reported by Halcón Resources Corporation for the previous quarter, Wall Street now forecasts -83.33% EPS growth.

Another recent and important Halcón Resources Corporation (NYSE:HK) news was published by Seekingalpha.com which published an article titled: “Halcon Resources – The Liquidity Question” on May 29, 2018.

Among 14 analysts covering Halcon Resources Corp (NYSE:HK), 11 have Buy rating, 1 Sell and 2 Hold. Therefore 79% are positive. Halcon Resources Corp had 31 analyst reports since August 28, 2015 according to SRatingsIntel. Barclays Capital upgraded it to “Hold” rating and $800 target in Thursday, July 13 report. The stock has “Buy” rating by Roth Capital on Tuesday, January 16. The stock of Halcón Resources Corporation (NYSE:HK) has “Hold” rating given on Tuesday, September 13 by Wunderlich. The rating was maintained by Roth Capital with “Buy” on Tuesday, August 1. The firm earned “Buy” rating on Friday, June 2 by Roth Capital. The stock of Halcón Resources Corporation (NYSE:HK) earned “Accumulate” rating by Johnson Rice on Wednesday, March 1. The firm has “Hold” rating by Johnson Rice given on Monday, April 18. The stock has “Buy” rating by Roth Capital on Friday, May 5. The stock of Halcón Resources Corporation (NYSE:HK) has “Buy” rating given on Thursday, October 19 by Johnson Rice. The stock of Halcón Resources Corporation (NYSE:HK) has “Buy” rating given on Tuesday, October 17 by Seaport Global.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company has market cap of $26.22 billion. The firm offers Soliris , a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It has a 59.82 P/E ratio. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia (HPP); and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency.

Among 29 analysts covering Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), 25 have Buy rating, 0 Sell and 4 Hold. Therefore 86% are positive. Alexion Pharmaceuticals Inc. had 111 analyst reports since July 27, 2015 according to SRatingsIntel. On Thursday, February 8 the stock rating was maintained by Jefferies with “Hold”. The firm has “Overweight” rating by Morgan Stanley given on Thursday, May 25. Jefferies maintained the shares of ALXN in report on Wednesday, June 7 with “Hold” rating. Leerink Swann maintained the shares of ALXN in report on Friday, July 28 with “Outperform” rating. Deutsche Bank maintained the stock with “Buy” rating in Friday, February 9 report. Citigroup initiated Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) on Thursday, February 25 with “Neutral” rating. SunTrust maintained the stock with “Buy” rating in Monday, October 23 report. As per Tuesday, June 13, the company rating was maintained by BMO Capital Markets. The stock has “Overweight” rating by PiperJaffray on Monday, October 23. As per Tuesday, November 29, the company rating was upgraded by Barclays Capital.

More notable recent Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) news were published by: Streetinsider.com which released: “Alexion Pharma (ALXN), Complement Pharma Announce Pact to Co-Develop Pre-Clinical Complement Inhibitor for …” on June 11, 2018, also Schaeffersresearch.com with their article: “2 Biotech Stocks That Could Blast Off This Summer” published on June 04, 2018, Investorplace.com published: “10 Stocks That Are Screaming Buys Right Now” on June 12, 2018. More interesting news about Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) were released by: Businesswire.com and their article: “Alexion and Complement Pharma Announce Partnership to Co-Develop Pre-Clinical Complement Inhibitor for …” published on June 11, 2018 as well as Streetinsider.com‘s news article titled: “Vertex Pharma (VRTX), Alexion Pharma (ALXN) Least Impacted from Trump Drug Policies – RBC” with publication date: May 15, 2018.

Since January 2, 2018, it had 1 insider buy, and 12 insider sales for $3.41 million activity. On Tuesday, February 6 Clancy Paul J sold $707,048 worth of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) or 6,079 shares. 2,119 shares valued at $248,474 were sold by O’Neill Julie on Monday, February 5. Another trade for 655 shares valued at $76,805 was made by Wagner Heidi L on Monday, February 5. COUGHLIN CHRISTOPHER J also bought $1.21 million worth of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) shares. 1,651 shares valued at $192,028 were sold by Goff Brian on Tuesday, February 6. $1.54M worth of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) was sold by HANTSON LUDWIG on Tuesday, February 6. $389,099 worth of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) was sold by Moriarty John B.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *